Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs METHOCARBAMOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: Tetanus-associated muscle spasms,Off-label: Postoperative muscle spasms
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Metabolized by the liver via dealkylation and hydroxylation. The major metabolic pathway involves O-dealkylation to form a glycinate conjugate, with CYP450 enzymes likely involved.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
38-45%, primarily bound to albumin.
Protein binding: 46-50% to albumin.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Volume of distribution: 0.6-0.8 L/kg. Clinical meaning: distributes widely into tissues, moderate Vd indicating extravascular distribution.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: high bioavailability, ~80-100% (well absorbed with first-pass metabolism to inactive conjugates). Intravenous: 100%.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Cr Cl <50 m L/min: Administer every 8-12 hours; Cr Cl <30 m L/min: Administer every 12 hours; hemodialysis: Supplementation not well-defined; avoid if possible due to propylene glycol content.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not recommended for children under 16 years; safety and efficacy not established.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Start at lower end of dosing range (e.g., 750 mg orally 4 times daily) due to increased risk of sedation and falls; monitor renal function and adjust accordingly.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
No FDA black box warning.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
May cause dizziness, drowsiness, or blurred vision; caution with activities requiring mental alertness. Use with caution in patients with hepatic impairment, renal impairment, or myasthenia gravis. Avoid concurrent use with other CNS depressants. May cause urine discoloration (brown, black, or blue).
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to methocarbamol or any component of the formulation; concomitant use of anticholinesterase drugs in patients with myasthenia gravis (contraindicated); known history of G6PD deficiency (relative, due to risk of hemolytic anemia).
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
No significant food interactions. Grapefruit juice does not affect methocarbamol. However, avoid alcohol entirely due to additive CNS depression.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate human studies. Second and third trimesters: Potential for neonatal CNS depression and hypotonia if used near term. Avoid use unless benefit outweighs risk.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Excreted in breast milk in small amounts; M/P ratio not established. No reported adverse effects in infants. Caution is advised due to potential for CNS depression or muscle weakness.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No established dose adjustment guidelines. Increased renal clearance during pregnancy may reduce serum levels; however, safety data insufficient. Use lowest effective dose for shortest duration.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Methocarbamol is a centrally acting muscle relaxant with sedative properties. Avoid or taper to prevent rebound muscle spasm. Monitor for CNS depression, especially when combined with alcohol or other CNS depressants. Use cautiously in elderly due to fall risk. May cause urine discoloration (brown, black, or blue-green) which is benign. Onset of action is within 30 minutes; maximal effect in 1-2 hours. Typical adult dose: 1.5-2 g PO QID for first 2-3 days, then 1 g QID.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication may cause drowsiness, dizziness, or blurred vision. Do not drive, operate machinery, or perform hazardous tasks until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation and risk of falls.,Notify your healthcare provider if you experience fever, rash, itching, or jaundice (yellowing of skin/eyes).,Urine may turn brown, black, or blue-green; this is harmless and not a cause for alarm.,Do not stop suddenly; gradual dose reduction is recommended to prevent withdrawal symptoms like muscle spasm or anxiety.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.
No interactions on record
"The coadministration of propofol, a GABA-A receptor agonist general anesthetic, with methocarbamol, a centrally acting muscle relaxant, can produce additive sedative and respiratory depressant effects. This interaction may lead to excessive sedation, prolonged recovery from anesthesia, and an increased risk of hypoxia or apnea. Clinically, patients may exhibit deeper levels of unconsciousness and require prolonged monitoring of respiratory function."
"Methocarbamol, a centrally acting muscle relaxant, potentiates the sedative effects of nabilone, a synthetic cannabinoid used for chemotherapy-induced nausea and vomiting. This additive central nervous system depression can lead to excessive drowsiness, dizziness, impaired motor coordination, and increased risk of falls or cognitive impairment. Clinically, patients may experience exacerbated sedation, confusion, and psychomotor slowing, particularly when initiating therapy or at higher doses."
"Concomitant use of methocarbamol and gabapentin enacarbil results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic neurotransmission and neuronal excitability. This synergistic interaction significantly increases the risk of excessive sedation, dizziness, and impaired psychomotor function, potentially leading to falls, cognitive deficits, or respiratory depression in susceptible patients. Clinical outcomes are dose-dependent and more pronounced in elderly patients or those with pre-existing CNS compromise."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs METHOCARBAMOL, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. METHOCARBAMOL is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and METHOCARBAMOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of METHOCARBAMOL is: METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and METHOCARBAMOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. METHOCARBAMOL is classified as Category A/B. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.